Appointments

Submit a Form

Questions

Submit a Form

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
2559 Genetic and molecular analysis of tumors of the Nervous system and their coveringsMain Campus  Brain
ABTC 120213-927Phase I Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent GlioblastomaMain Campus Phase 1Brain, Glioblastoma
BTTC 131212-581Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade GliomasMain Campus  Brain, High Grade Glioma
BTTC 331213-042A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High Grade GliomasMain Campus  Brain
CASE 1307296Ohio Brain Tumor Study (OBTS)Main Campus  Brain
CASE 331313-445A prospective phase II trial of NovoTTF-100A with Bevacizumab (Avastin) in Patients with Recurrent GlioblastomaMain Campus Phase 2Brain, Glioblastoma
CASE 4309CC845Phase I/II Trial of Radiosurgery Plus Bevacizumab in Patients with Recurrent / Progressive GlioblastomaMain Campus Phase 1, Phase 2Brain
CASE 441313-1081Phase II study of Radioimmunotherapy with Zevalin (Ibritumomab Tiuxetan) Therapy for Patients with Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL) Main Campus Phase 2Brain, Lymphoma, PCNSL (Primary Central Nervous System Lymphoma)
CASE 731213-143Neoadjuvant Radiosurgery for resectable brain metastases: Phase I/II StudyMain Campus Phase 1, Phase 2Brain
CASE 831213-221Dose Escalation for Larger Brain Metastases: Phase I/II StudyMain Campus Phase 1, Phase 2Brain
DFCI 231212-940An open-label, Phase II Trial of Orally Administered PF-00299804 in Adult Patients with Relapsed/Recurrent Glioblastoma (GBM)Main Campus Phase 2Brain, Glioblastoma
MONT 131112-007LAASR: Laser Ablation After Stereotactic RadiosurgeryMain Campus  Brain
NCCTG107C12-123N107C A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) compared with whole brain radiotherapy (WBRT) for resected metastatic brain diseaseMain Campus Phase 3Brain
NCTG 1310CC00039; N0577Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic GliomaBeachwood, Fairview, Hillcrest, Independence, Main Campus, Wooster Phase 3Brain
NOVO 1308931Prospective, Multi-center Trial of NovoTTF-100A Together with Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBMMain Campus  Brain
RTOG 0834CC945Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.Main Campus Phase 3Brain
RTOG 111412-583A Phase II Randomized Study of Rituximab, Methotrexate, Vincristine and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System LymphomaMain Campus Phase 2Brain
RTOG 111913-551Phase II Randomized study of whole brain radiotherapy in combination with concurrent lapatinib in patients with brain metastasis from HER2-Positive Breast cancer. A collaborative study of RTOG and KROG.Beachwood, Fairview, Hillcrest, Independence, North Coast Cancer, Parma, Strongsville, Wooster Phase 2Brain, Breast
RTOG092513-474Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II GliomaMain Campus  Brain
TOG 1309CC949A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients with Recurrent Glioblastoma MultiformeMain Campus Phase 1Brain, Glioblastoma
12

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.